Independent French company Servier has acquired Pixuvri (pixantrone), a drug approved in the European Union as monotherapy for multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, from USA-based CTI BioPharma (Nasdaq: CTIC).
Servier previously commercialized Pixuvri in all countries where it is approved, which also include Iceland, Israel, Liechtenstein, Myanmar, Norway, Pakistan, Russia and Ukraine, under an exclusive license from CTI BioPharma.
Terms of the acquisition have not been disclosed. The acquired drug is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze